Drugs / Petosemtamab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03526835 | May 2018 → Nov 2025 overdue | colorectal cancer, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma +2 | Merus B.V. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07353957 | Mar 2025 → May 2028 | non-small cell squamous lung carcinoma | Merus B.V. | Withdrawn | No outcome recorded Stop: Business |
| Phase 34 trials | ||||||
| Phase 3 | NCT07775287 | Oct 2026 → Mar 2029 expected | colorectal cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07702032 | Aug 2026 → Jul 2029 expected | colorectal cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT06525220 | Sep 2024 → Jan 2028 expected | head and neck squamous cell carcinoma | Merus B.V. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06496178 | Jun 2024 → Feb 2028 expected | head and neck squamous cell carcinoma | Merus B.V. | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Petosemtamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06525220 ↗ |
| Known as | MCLA-158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03526835 ↗ |
| Known as | MCLA-158 + FOLFOX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03526835 ↗ |
| Modality | Monoclonal antibody | “full-length IgG1 bispecific antibody targeting EGFR and LGR5” NCT03526835 ↗ |
| Route | Intravenous | “receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks” NCT03526835 ↗ |
| Target | EGFR | “full-length IgG1 bispecific antibody targeting EGFR and LGR5” NCT03526835 ↗ |
| Target | LGR5 | “full-length IgG1 bispecific antibody targeting EGFR and LGR5” NCT03526835 ↗ |